Article
The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009.
Oncotarget - 6 Dec 2016
Zhang Xiaoxin, Xu Qiaoqiao, Yang Lirun, Lai Yueyang, Zhang Zhuangzhuang, Han Chao, Jiang Chizhou, Li Jiahuang, Shi Yixin, Hua Zi-Chun
Abstract excerpt
VNP20009 is a very effective anti-cancer agent and can specifically target tumors and inhibit tumor growth. It was assumed that the tumor targeting ability of VNP20009 correlated to its anticancer capacity. However, our observation contradicted to this assumption. Three VNP20009 mutant strains (ΔslyA, ΔSTM3120 and ΔhtrA) with reduced fitness in normal tissues and unchanged fitness in tumors partially or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.